The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies
Open accessAbstract
Background Whether triglyceride-mediated pathways are causally relevant to coronary heart disease is uncertain. We studied a genetic variant that regulates triglyceride concentration to help judge likelihood of causality.Methods We assessed the -1131T>C (rs662799) promoter polymorphism of the apolipoprotein A5 (APOA5) gene in relation to triglyceride concentration, several other risk factors, and risk of coronary heart disease. We compared disease risk for genetically-raised triglyceride concentration (20,842 patients with coronary heart disease, 35,206 controls) with that recorded for equivalent differences in circulating triglyceride concentration in prospective studies (302 430 participants with no history of cardiovascular disease; 12,785 incident cases of coronary heart disease during 2.79 million person-years at risk). We analysed -1131T>C in 1795 people without a history of cardiovascular disease who had information about lipoprotein concentration and diameter obtained by nuclear magnetic resonance spectroscopy.Findings The minor allele frequency of -1131T>C was 8% (95% CI 7-9). -1131T>C was not significantly associated with several non-lipid risk factors or LDL cholesterol, and it was modestly associated with lower HDL cholesterol (mean difference per C allele 3.5% [95% CI 2.6-4.6]; 0.053 mmol/L [0.039-0.068]), lower apolipoprotein AI (1.3% [0.3-2.3]; 0.023 g/L [0.005-0.041]), and higher apolipoprotein B (3.2% [1.3-5.1]; 0.027 g/L [0.011-0.043]). By contrast, for every C allele inherited, mean triglyceride concentration was 16.0% (95% CI 12.9-18.7), or 0.25 mmol/L (0.20-0.29), higher (p=4.4x10(-24)). The odds ratio for coronary heart disease was 1.18 (95% CI 1.11-1.26; p=2.6x10(-7)) per C allele, which was concordant with the hazard ratio of 1.10 (95% CI 1.08-1.12) per 16% higher triglyceride concentration recorded in prospective studies. -1131T>C was significantly associated with higher VLDL particle concentration (mean difference per C allele 12.2 nmol/L [95% CI 7.7-16.7]; p=9.3x10(-8)) and smaller HDL particle size (0.14 nm [0.08-0.20]; p=7.0x10(-5)), factors that could mediate the effects of triglyceride.Interpretation These data are consistent with a causal association between triglyceride-mediated pathways and coronary heart disease.Funding British Heart Foundation, UK Medical Research Council, Novartis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Non-HDL-C also includes the atherogenic TG-rich lipoproteins (VLDL, IDL and remnants), which is essential considering the recent information from genome-wide association studies (GWASs) and Mendelian randomization 76,86 - 89 supporting TGs and remnant particles as causative factors in atherogenesis.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [87]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although the CVD risk is increased if fasting TGs are . 1.7 mmol/ L (150 mg/dL), 87 the use of drugs to lower TGs may only be considered in high-risk subjects when TGs are . 2.3 mmol/L (200 mg/dL) and cannot be lowered by lifestyle measures.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [87]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The results of the current study extend those findings by suggesting that triglyceride-rich remnant particles have approximately the same effect on the risk of cardiovascular disease as LDL particles.”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [28]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The association between triglycerides and cardiovascular (CV) risk is well established from epidemiological studies,1-5 genome-wide analyses,6-8 and Mendelian randomization studies.9,10”
In the citing paper
“Therefore, the clinical benefit of therapies that lower LDL-C by reducing LDL particle mass will be proportional to the absolute reduction in LDLC, because-on average-the reduction in LDL-C and LDL particles will be concordant [34,50,54,55].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [55]
In the citing paper
“The beneficial effect of ezetimibe is also supported by genetic studies of mutations in NPC1L1; naturally occurring mutations that inactivate the protein were found to be associated with reduced plasma LDL-C and reduced risk for CAD [55,269,270].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [55]
In the citing paper
“Although the role of TG as a risk factor for CVD has been strongly debated, recent data strongly favour the role of TG-rich lipoproteins as a risk factor for CVD.121”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [121]
In the citing paper
“The causative role of HDL-C for protection against CVD has been questioned in several studies utilizing Mendelian randomization. 87,89,91,92”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [87]
In the citing paper
“Although the role of TGs as a risk factor for CVD has been strongly debated, recent data favour the role of TG-rich lipoproteins as a risk factor for CVD.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [87]
In the citing paper
“The causative role of HDL-C for protection against CVD has been questioned in several studies utilizing Mendelian randomization.87,89,91,92”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [87]
In the citing paper
“recent data favour the role of TG-rich lipoproteins as a risk factor for CVD.87”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [87]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Davey Smith, G., & Ebrahim, S. (2003) · International Journal of Epidemiology · doi:10.1093/ije/dyg070 · Cited by 5,882
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Tunstall-Pedoe, H., Kuulasmaa, K., Amouyel, P., Arveiler, D., Rajakangas, A.-M., & Pająk, A. (1994) · Circulation · doi:10.1161/01.cir.90.1.583 · Cited by 2,260
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408
Kathiresan, S., Melander, O., Guiducci, C., Surti, A., Burtt, N. P., Rieder, M. J., Cooper, G. M., Roos, C., Voight, B. F., Havulinna, A. S., et al. (2008) · Nature Genetics · doi:10.1038/ng.75 · Cited by 1,386
Thompson, A. (2008) · JAMA · doi:10.1001/jama.299.23.2777 · Cited by 498
Sattar, N. A., McConnachie, A., Shaper, A. G., Blauw, G. J., Buckley, B. M., de Craen, A. J. M., Ford, I., Forouhi, N. G., Freeman, D. J., Jukema, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60602-9 · Cited by 492
Keating, B. J., Tischfield, S. E., Murray, S. S., Bhangale, T., Price, T. S., Glessner, J., Galver, L., Barrett, J. C., Grant, S. F. A., Farlow, D., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003583 · Cited by 373
Cited by
Sorted by citations
Items 501–600 of 716
Fadaei, R., Azadi, S. M., Laher, I., & Khazaie, H. (2022) · Laboratory Medicine · doi:10.1093/labmed/lmac073 · Cited by 5
Yamaji, T., Harada, T., Kajikawa, M., Maruhashi, T., Kishimoto, S., Yusoff, F. M., Chayama, K., Goto, C., Nakashima, A., Tomiyama, H., et al. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64416 · Cited by 5
Beyond Statins: Who and When to Prescribe?
Ganda, O. P. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1087-0 · Cited by 5
Palmisano, B. T., Zhu, L., Litts, B., Burman, A., Yu, S., Neuman, J. C., Anozie, U., Luu, T. N., Edington, E. M., & Stafford, J. M. (2021) · Metabolites · doi:10.3390/metabo11050330 · Cited by 7
Lipid disorders in Chinese populations
Hu, M., Thomas, G. N., & Tomlinson, B. (2011) · Clinical Lipidology · doi:10.2217/clp.11.47 · Cited by 5
Hou, Y., Tian, P., Song, G., Song, A., Liu, D., Wang, Z., Shi, Y., Tang, Y., Wang, X., Li, L., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1502792 · Cited by 4
Alcover, S., Ramos-Regalado, L., Muñoz‐García, N., Girón, G. O., Otero, S., López, S., Padró, T., Badimón, L., & Vilahur, G. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag187 · Cited by 4
Triglycerides and Atherosclerotic Cardiovascular Disease.
Puri, R., Mehta, V., Iyengar, S. S., Narasingan, S. N., Duell, P. B., Sattur, G. B., Vijayaraghavan, K., Mohan, J. C., Wangnoo, S. K., Dalal, J. J., et al. (2020) · PubMed · Cited by 4
Dimeji, I. Y., Olufemi, M. A., & Bolanle, O. I. (2021) · Nigerian Journal of Experimental and Clinical Biosciences · doi:10.4103/njecp.njecp_49_20 · Cited by 4
Pang, J., Li, S., Chan, D. C., SULLIVAN, D. R., Woodward, A.-M., & Watts, G. F. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000715 · Cited by 4
Fan, W., Philip, S., Toth, P. P., Granowitz, C. B., & Wong, N. D. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100087 · Cited by 4
Rosenthal, E. A., Crosslin, D. R., GORDON, A. S., Carrell, D., Stanaway, I. B., Larson, E. B., Grafton, J. R., Wei, W., Denny, J. C., Feng, Q., et al. (2021) · BMC Medical Genomics · doi:10.1186/s12920-020-00854-2 · Cited by 4
Association and diagnostic value of a novel uric acid index to cardiovascular risk
Rojas-Humpire, R., Jáuregui-Rodríguez, K., Albornoz, S., Mamani, P. G. R., Gutierrez-Ajalcriña, R., & Huancahuire‐Vega, S. (2021) · Practical Laboratory Medicine · doi:10.1016/j.plabm.2021.e00247 · Cited by 4
Treatment of Hypertriglyceridemia: A Review of Therapies in the Pipeline
Xu, J., & Ashjian, E. J. (2021) · Journal of Pharmacy Practice · doi:10.1177/08971900211053489 · Cited by 4
Kawashima, Y., Eguchi, Y., Yamazaki, T., Karahashi, M., Kawai, H. F., & Kudo, N. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.246165 · Cited by 4
Epidemiologic Characterization of Risk for Cardiovascular Diseases
Maki, K. C., Dicklin, M. R., & Nieman, K. M. (2018) · Contemporary cardiology · doi:10.1007/978-3-319-97622-8_1 · Cited by 4
Investigational drugs in development for hypertriglyceridemia: a coming-of-age story
Rhainds, D., Brodeur, M. R., & Tardif, J. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1696772 · Cited by 4
Risk of cardiovascular disease after preventive salpingo-oophorectomy
Johansen, N., Tonstad, S., Liavaag, A. H., Selmer, R. M., Tanbo, T. G., & Michelsen, T. M. (2020) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2019-000856 · Cited by 4
Adam, M. F., Hutahaean, Y. O., & Siagian, L. R. D. (2020) · Jurnal Kedokteran Mulawarman · doi:10.30872/j.ked.mulawarman.v7i2.4293 · Cited by 4
Campbell, A. W., Sinatra, D. S., Zhang, Z., & Sinatra, S. T. (2020) · PubMed · Cited by 4
Lee, Y., Lee, J., Chung, H., Woo, J., Lee, B.-C., & Kim, W. (2022) · Life · doi:10.3390/life12030408 · Cited by 4
Pedro‐Botet, J., Barrios, V., Sánchez‐Margalet, V., Tamargo, J. L., Arrieta, F., Gámez, J. M., Gimeno-Orna, J. A., Escobar, C., Gómez‐Doblas, J. J., & Pérez, A. (2022) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2022.03.004 · Cited by 5
APOA5 haplotypes determine triglyceride decrease after lifestyle induced weight loss in children
Zlatohlávek, L., Vrablı́k, M., Češka, R., Adámková, V., Urbanová, Z., Prusíková, M., Vašícková, L., & Hubacek, J. A. (2012) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2012.05.001 · Cited by 4
Sun, J., Yuan, H., Hu, H., & Yu, H. M. (2016) · Genetics and Molecular Research · doi:10.4238/gmr.15016954 · Cited by 4
Sun, Y., Zhou, R., & Chen, D. M. (2015) · Genetics and Molecular Research · doi:10.4238/2015.december.23.9 · Cited by 4
The insulin resistance syndrome
Sattar, N. A., Welsh, P. I., & Preiss, D. (2015) · doi:10.1002/9781118387658.ch23 · Cited by 4
Choice of medical therapy to lower triglycerides in those at risk of pancreatitis
Preiss, D., & Sattar, N. A. (2013) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000029 · Cited by 4
Triglyceride-mediated pathways and coronary heart disease
Zeng, D., Zheng, Q., & Ou, D. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61449-3 · Cited by 4
Modified Lipids as Functional Ingredients for Chronic Disease Management
Amenyenu, E., Abbah, Q. S., Fawole, A. O., & Onuh, J. O. (2025) · Journal of Food Science · doi:10.1111/1750-3841.70526 · Cited by 3
Alodainy, W. A. (2022) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2022.95248 · Cited by 3
ω‑3 fatty acids in atherosclerotic cardiovascular disease (Review)
Xie, X., Liu, X., Li, R., Ling, F., & Huang, F. (2024) · Biomedical Reports · doi:10.3892/br.2024.1782 · Cited by 6
Shen, F., Chu, C., Chen, J., Kuo, C., Hsu, C., Lin, C., Sheen, Y., Su, S., Tien, K., Lu, C., et al. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14222 · Cited by 3
Ruiz‐García, A., Pallarés‐Carratalá, V., Serrano-Cumplido, A., Pascual-Fuster, V., Arranz-Martínez, E., & Escobar, C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14113940 · Cited by 3
Shen, W. H., Luo, R., Yang, L., Li, Z., Hou, X., & Liu, Z. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.147363 · Cited by 3
Nutrition, Genetics, and Cardiovascular Disease
Qi, L. (2012) · Current Nutrition Reports · doi:10.1007/s13668-012-0008-0 · Cited by 4
Tratamiento lipídico en la guía europea de dislipemias
Luengo, E. (2012) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(12)70041-9 · Cited by 3
Yang, Y., Walijee, S. M., Jing, J., Zhao, S., & Peng, D. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.02.004 · Cited by 3
Hypertriglyceridemia in obese subjects: Caused by reduced apolipoprotein A5 plasma levels?
Heeren, J., & Merkel, M. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.06.020 · Cited by 3
Aledo, R., Padró, T., Mata, P., Rodrigo Alonso, K., & Badimón, L. (2014) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2014.04.015 · Cited by 3
Prescription omega-3 carboxylic acids for the treatment of severe hypertriglyceridemia
Maki, K. C., Poulos, S. P., Phillips, A., & Lawless, A. L. (2014) · Clinical Lipidology · doi:10.2217/clp.14.39 · Cited by 3
Genetics of Atherosclerotic Cardiovascular Disease
Qasim, A., & Reilly, M. P. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-383834-6.00061-6 · Cited by 4
Brown, A. L., & Brown, J. M. (2017) · Journal of Lipid Research · doi:10.1194/jlr.c077131 · Cited by 3
Toxicological effect of Artemisinin-Based Combination Therapies plus Paracetamol in malaria patients
Aghahowa, S., Ozolua, R. I., Bafor, E. E., Obarisiagbon, P. A., & Isah, A. O. (2021) · Toxicology Reports · doi:10.1016/j.toxrep.2021.11.007 · Cited by 3
Yıldız, M., Miedema, M. D., Murthy, A., Henry, T. D., Bergstedt, S., Okeson, B. K., Schmidt, C. W., Volpenhein, L., Garcia, S. A., Sharkey, S. W., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e17308 · Cited by 4
Association of APOA5 −1131T>C Polymorphism and Serum Lipid Levels in Patients with Type 2 Diabetes
Ćelap, I., Šimundić, A.-M., Nikolac, N., Kačkov, S., & Katalinić, D. (2013) · DNA and Cell Biology · doi:10.1089/dna.2013.2099 · Cited by 3
Hypertriglyceridaemia in statin‐treated type 2 diabetic patients
Hamilton, S. J., Chew, G., Davis, T., Stuckey, B. G. A., & Watts, G. F. (2011) · Practical Diabetes · doi:10.1002/pdi.1610 · Cited by 3
Yoo, J., Cho, Y. H., Gu, H.-G., Kim, B.-Y., & Yun, Y.-J. (2014) · 대한한의학회지 · doi:10.13048/jkm.14012 · Cited by 3
Optimal Non-invasive Strategies to Reduce Recurrent Atherosclerotic Cardiovascular Disease Risk
Jones‐O’Connor, M., & Natarajan, P. (2019) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-019-0741-4 · Cited by 3
Tocilizumab‐related hypertriglyceridemia is independent of key molecules regulating lipid metabolism
Ferraz‐Amaro, I., Santos‐Concepción, S., Castro‐Hernández, J., Hernández-Hernández, V., Segura, B. T., Luna, C., Delgado-Frías, E., & Díaz‐González, F. (2023) · European Journal of Clinical Investigation · doi:10.1111/eci.14006 · Cited by 2
Genomics and Pharmacogenomics of Lipid-Lowering Therapies
Docherty, K. F., & Padmanabhan, S. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386882-4.00031-1 · Cited by 3
NEW POSSIBILITIES OF HYPOLIPIDEMIC THERAPY
Benimetskaya, K., Atyukov, P. A., Astrakov, S. V., & Ragino, Y. I. (2017) · Siberian medical review · doi:10.20333/2500136-2017-4-65-81 · Cited by 3
Triglyceride-mediated pathways and coronary heart disease
Dallongeville, J., & Meirhaeghe, A. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61448-1 · Cited by 3
Lifestyle Approaches to Lowering Triglycerides
Hankinson, S. J., Miller, M. J., & Freeman, A. M. (2021) · Contemporary cardiology · doi:10.1007/978-3-030-78177-4_14 · Cited by 2
Current Perspectives of Diabetic Dyslipidemia and Treatment Modalities
Akkuş, G. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673336501241001093417 · Cited by 2
Hipertrigliceridemia (> 150 mg/dl) como marcador de riesgo cardiovascular
López-Miranda, J. (2025) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2025.500822 · Cited by 2
Association between alcohol consumption and carotid atherosclerosis in Russia
Mitkin, N. A., Ryabikov, A. N., Алексеевна, М. О., Guseynova, U. G., Владиславовна, С. Н., Soloviev, A. G., Malyutina, S. K., & Kudryavtsev, A. V. (2025) · Scientific Reports · doi:10.1038/s41598-025-16290-0 · Cited by 2
Cho, J. H., Ahn, J., Kang, M. G., Bae, J. S., Koh, J.-S., Jung, M. K., Kim, S., Gorog, D. A., Tantry, U. S., Gurbel, P. A., et al. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102498 · Cited by 2
Bouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2026) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2026.01.001 · Cited by 2
Triglyceride reduction after MI and major adverse outcomes in SWEDEHEART—insights for future trials
Schubert, J. R., Hagström, E., Westerbergh, J., Leósdóttir, M., & Ray, K. K. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag076 · Cited by 4
Fathy, M. M., Wahab, A. A.-A., Tabozada, S., Ibrahim, M., Aref, W., & Hamid, M. A.-A. (2012) · Comparative Clinical Pathology · doi:10.1007/s00580-012-1558-7 · Cited by 2
Aledo, R., Padró, T., Mata, P., Rodrigo Alonso, K., & Badimón, L. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2014.04.017 · Cited by 2
Therapie von Fettstoffwechselstörungen
Custodis, F., & Laufs, U. (2014) · Herz · doi:10.1007/s00059-013-4013-x · Cited by 2
Epidemiology of Atherosclerotic Cardiovascular Disease
Hirahatake, K. M., Dicklin, M. R., & Maki, K. C. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_5 · Cited by 2
Psychophysiological Bases of Disease
Steptoe, A., & Poole, L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818697-8.00138-2 · Cited by 2
Yu, S., Sun, H. Y., & Yoo, B. W. (2023) · Journal of Yeungnam Medical Science · doi:10.12701/jyms.2023.00528 · Cited by 2
Management of lipid abnormalities in metabolic syndrome
Fariduddin, M. M., & Naik, R. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00048-7 · Cited by 2
Huang, X., Sun, T., Zhang, B., Ma, M., Chen, Z., Zhao, Z., Dong, S., & Zhou, Y. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2458200 · Cited by 2
Genetic and Nutritional Interactions in Cardiovascular Disease
Caterina, R. D. (2011) · World review of nutrition and dietetics · doi:10.1159/000327803 · Cited by 2
Recent Findings from Mendelian Randomization Studies of Cardiovascular Disease
Brown, I., & Elliott, P. (2010) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-010-0127-3 · Cited by 2
Liu, J., Zhao, M., Zhu, Y., Zheng, L., & Yin, Y. (2020) · PROTEOMICS · doi:10.1002/pmic.202000050 · Cited by 2
Toroghi, M. K., Bosley, J., Powell, L. M., Zhang, Y., Yang, F., Pu, X., Davis, J. D., & Al-Huniti, N. H. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12694 · Cited by 2
Chong, M.-Y., & Han, I. (2021) · Journal of the East Asian Society of Dietary Life · doi:10.17495/easdl.2021.10.31.5.299 · Cited by 2
Statin-induced necrotizing autoimmune myopathy (SINAM): case report and review of the literature
Cornelis, L., Duyck, J., Dedeurwaerdere, F., Schoenmakere, G. D., & Malfait, T. L. A. (2022) · Acta Clinica Belgica · doi:10.1080/17843286.2022.2156701 · Cited by 2
Cai, H., Zheng, R., Wu, N., Hu, J., Wang, R., Chi, J., Zhang, W., Zhao, L., Cheng, H. B., Chen, A., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15102377 · Cited by 2
High-Density Lipoprotein Cholesterol and Triglycerides in Coronary Heart Disease Risk Assessment
Miller, M. J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00009-8 · Cited by 2
Intergenerational implications of alcohol intake: metabolic disorders in alcohol-naïve rat offspring
Mierzejewski, P., Zakrzewska-Sito, A., Kuczyńska, J., Wyszogrodzka, E., & Dominiak, M. (2020) · PeerJ · doi:10.7717/peerj.9886 · Cited by 2
Working towards full eradication of lipid-driven cardiovascular risk?
Nurmohamed, N. S., & Stroes, E. S. G. (2021) · Netherlands Heart Journal · doi:10.1007/s12471-021-01600-8 · Cited by 2
Pathogenesis of atherosclerosis: lipid metabolism
Wiklund, O., & Borén, J. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780198755777.003.0011 · Cited by 2
Evidence of Pharmaceutical Innovation and Therapeutic Enthusiasm
Redberg, R. F. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2012.382 · Cited by 2
Martín, I. S. M., Olivares, J. A. B., Vilar, E., Cabañas, M. C., & Yurrita, L. C. (2019) · Research in Cardiovascular Medicine · doi:10.4103/rcm.rcm_10_19 · Cited by 1
Genotypic stratification of risk of acute cerebral circulation disorder
Александрович, Н. Д., Чернова, А. А., Nikulina, S. Y., Prokopenko, S. V., & Mar'ina, N. M. (2021) · Cardiosomatics · doi:10.17816/22217185.2021.4.201262 · Cited by 1
Does lowering triglycerides reduce cardiovascular risk?
de Moura, J. P. (2019) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repce.2019.11.005 · Cited by 1
Cardiovascular risk factors and all-cause mortality in older age (15-year cohort study)
Malyutina, S. K., Симонова, Г. И., Rymar, O. D., Викторовна, М. Е., Shapkina, M., Avdeeva, E. M., Mustafina, S. V., & Вахтанговна, Д. Д. (2024) · Ateroscleroz · doi:10.52727/2078-256x-2024-20-3-229-245 · Cited by 1
Dong, Z., Li, J., Wang, S., Guo, C., Lu, S., Wang, S., & Fu, X. (2024) · Lecture notes in computer science · doi:10.1007/978-3-031-77954-1_4 · Cited by 1
Hypertriglyceridemia (> 150 mg/dL) as a marker of cardiovascular risk
López-Miranda, J. (2025) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2025.500822 · Cited by 1
Wulff, A. B., Varbo, A., Nordestgaard, A. G., & Nordestgaard, B. G. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2639678 · Cited by 2
The evaporation of positive genetic association findings. When time has come to go
Kronenberg, F., & Lamina, C. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.07.049 · Cited by 1
Triglyceride-rich lipoproteins and HDL: What do recent trials tell us?
Stock, J. K. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.03.011 · Cited by 1
Yang, G., Lei, M.-M., Yu, C.-L., Liu, X.-X., An, Z., & Song, C.-L. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0110-6 · Cited by 1
Parental brevity linked to cardiometabolic risk in diabetic descendants
Hermans, M. P., Ahn, S. A., & Rousseau, M. F. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.11.005 · Cited by 1
Oikonomou, E. K., Siasos, G., & Tousoulis, D. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.09.059 · Cited by 1
Role of Conventional Risk Factors in Genetic Susceptibility to Cardiovascular Diseases
Swerdlow, D. I., Michail, M., & Zacharias, K. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803312-8.00008-2 · Cited by 2
Martín, I. S. M., Rojo, S. S., Vilar, E. G., Yurrita, L. C., & Olivares, J. A. B. (2019) · Annals of Pediatric Cardiology · doi:10.4103/apc.apc_86_18 · Cited by 1
Translating Evidence From Clinical Trials of omega-3 Fatty Acids to Clinical Practice
Nelson, A. J., & Nicholls, S. J. (2020) · Future Cardiology · doi:10.2217/fca-2019-0031 · Cited by 1
INNOVATIONS IN DIAGNOSTICS AND TREATMENT OF PATIENTS WITH HYPERTRIGLYCERIDEMIA
Симерзин, В. В., Fatenkov, O. V., Gagloeva, I. V., Galkina, M. A., Panisheva, Y. A., & Krasovskaya, M. A. (2017) · Science and Innovations in Medicine · doi:10.35693/2500-1388-2017-0-1-43-51 · Cited by 1
Hypertriglycéridémies, démarche clinique et thérapeutique
Lecerf, J. (2020) · Pratiques en nutrition · doi:10.1016/j.pranut.2020.06.010 · Cited by 1
Bases genéticas de las hipertrigliceridemias
Candás‐Estébanez, B., Padró‐Miquel, A., & Esteve-Luque, V. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2021.03.003 · Cited by 1
Helvacı, M. R., Altıntaşž, E., Yalçın, A., Muftuoglu, O. E., Abyad, A., & Pocock, L. (2022) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2022.95242 · Cited by 1
Epidemiology of Atherosclerotic Vascular Diseases
Andersson, C., & O’Donnell, C. J. (2015) · Springer eBooks · doi:10.1007/978-3-642-37078-6_46 · Cited by 1
HDL colesterol, protector de enfermedad cardiovascular: calidad vs. cantidad
Stoll, A. I. (2019) · Revista de Investigación de la Universidad Norbert Wiener · doi:10.37768/unw.rinv.05.01.011 · Cited by 1
Metadata
- Authors
- ‡
- Affiliations
- University of Cambridge (GB)
- Corresponding author
- ‡
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2010-05
- Volume
- 375
- Issue
- 9726
- Pages
- 1634-1639
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC2867029
- OpenAlex
- W2144516660
- Cited by
- 716
- References
- 37
- Citations by year
- 2026: 10 · 2025: 24 · 2024: 29 · 2023: 29 · 2022: 47 · 2021: 49 · 2020: 53 · 2019: 55 · 2018: 50 · 2017: 36 · 2016: 51 · 2015: 51 · 2014: 48 · 2013: 45 · 2012: 47
- FWCI
- 62.17
- Type
- journal article
- Language
- en
- Update notices
- erratum (2010-07-10)
- Open access
- bronze
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion, other-oa)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Bristol Research (University of Bristol) (publishedVersion)
- Socio-Environmental Systems Modeling (acceptedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion)
- Leicester Research Archive (University of Leicester) (submittedVersion, other-oa)
- Explore Bristol Research (submittedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- British Heart Foundation
- Novartis
- Medical Research Council
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- triglycerides, coronary artery disease, APOA5, APOA5 -1131T>C polymorphism, genetic association, triglyceride concentration, HDL cholesterol, apolipoprotein A-I, apolipoprotein B, lipoprotein concentration, lipoprotein particle size, causal inference, genetic risk factors
- MeSH terms
- Apolipoprotein A-V, Apolipoproteins, Apolipoproteins A, Coronary Disease, Gene Frequency, Genotype, Humans, Lipids, Lipoproteins, HDL, Lipoproteins, LDL, Lipoproteins, VLDL, Particle Size, Promoter Regions, Genetic, Risk Factors, Triglycerides, Polymorphism, Single Nucleotide, Mendelian Randomization Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
